Research led by the SKiN Center for Dermatology observed substantial clearance of scalp and body psoriasis and rapid itch ...

A total of 432 patients (56.3% women) aged 12 and older with psoriasis on the scalp and body were randomly assigned to two groups, one of which used roflumilast foam 0.3% once a day for eight ...

Icotrokinra showed rapid efficacy among adults and adolescents with at least moderate psoriasis. Most participants with scalp psoriasis treated with icotrokinra achieved the study’s primary ...

Results showed 66% of patients treated with icotrokinra achieved an ss-IGA score of 0/1 and 77% achieved a sPGA-G score of 0/1, compared with 11% and 21% receiving placebo, respectively, at week 16.

Virginia Gov. Glenn Youngkin has vetoed a bill that would have allowed African American history courses to count toward high school graduation requirements. The measure, which was introduced in ...

Once-daily roflumilast foam, 0.3% (Zoryve) significantly improved scalp and body symptoms of plaque psoriasis in a phase III trial. Improvements in scalp itch were also greater for patients ...

African American history has always suffered from neglect. But currently it is under attack. The assault comes from two disparate sources: one White; one Black. The onslaught by these reactionary ...

66% of patients with scalp psoriasis and 77% with genital psoriasis treated with investigational icotrokinra achieved site-specific clear or almost clear skin at Week 16 Icotrokinra continues to ...

Data from icotrokinra ICONIC-TOTAL show 66% of patients with scalp psoriasis and 77% with genital psoriasis ... It is estimated that 8 million Americans and more than 125 million people worldwide live ...

Data presented at the 2025 Society for Investigative Dermatology (SID) Annual Meeting show 57% of patients treated with once daily icotrokinra achieved the study's primary endpoint with an ...